title: Non-AIDS-defining cancers.
abstract: As HIV-infected patients are living longer, non-AIDS-defining cancers are increasing in number and now constitute the majority of cancers diagnosed in the HIV-infected population. The excess incidence of Hodgkin lymphoma and head and neck and liver cancers has been increasing among HIV-infected individuals. Breast and lung cancers appear to occur earlier in the HIV-infected population; Hodgkin lymphoma appears to have a later onset, reflecting the fact that most cases in the HIV-infected population are related to Epstein-Barr virus infection, which is generally seen in older rather than younger individuals. Mortality from Hodgkin lymphoma and lung and prostate cancers is higher among HIV-infected individuals than HIV-uninfected individuals. The greater risk of cancer in the HIV-infected population may be due to a number of factors, including more rapid immunosenescence. At a minimum, age- and sex-appropriate cancer screenings should be performed in all HIV-infected patients, and patients should be counseled on measures to reduce cancer risk. This article summarizes a presentation by Ronald T. Mitsuyasu, MD, at the IAS-USA continuing education program held in San Francisco, California, in March 2013.
authors.affiliation: University of California Los Angeles (UCLA) and UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, CA, USA.
authors.forename: Ronald T
authors.initials: RT
authors.lastname: Mitsuyasu
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D001943:Breast Neoplasms / Q000453:epidemiology; D006258:Head and Neck Neoplasms / Q000453:epidemiology; D006689:Hodgkin Disease / Q000453:epidemiology; D006801:Humans; D008175:Lung Neoplasms / Q000453:epidemiology; D008297:Male; D009369:Neoplasms / Q000453:epidemiology* / Q000209:etiology* / Q000401:mortality; D011471:Prostatic Neoplasms / Q000453:epidemiology; D018570:Risk Assessment; D016019:Survival Analysis
references.citation: N Engl J Med. 2011 Aug 4;365(5):395-409
references.pmid: 21714641
references.citation: J Natl Cancer Inst. 2011 May 4;103(9):753-62
references.pmid: 21483021
references.citation: Am J Gastroenterol. 2005 Aug;100(8):1805-12
references.pmid: 16086718
references.citation: Lancet Oncol. 2013 Apr;14(4):346-53
references.pmid: 23499546
references.citation: Cancer. 2010 Nov 15;116(22):5306-15
references.pmid: 20661911
references.citation: Ann Intern Med. 2010 Oct 5;153(7):452-60
references.pmid: 20921544
references.citation: J Infect Dis. 2010 Oct 15;202(8):1246-53
references.pmid: 20812850
references.citation: Clin Infect Dis. 2006 Jul 15;43(2):223-33
references.pmid: 16779751
references.citation: Clin Infect Dis. 2008 Aug 15;47(4):542-53
references.pmid: 18627268
references.citation: PLoS One. 2011 Jan 26;6(1):e16459
references.pmid: 21298072
references.citation: Curr HIV Res. 2009 Jul;7(4):365-77
references.pmid: 19601771
references.citation: Exp Gerontol. 1998 May;33(3):267-82
references.pmid: 9615924
references.citation: AIDS. 2014 Apr 24;28(7):1007-14
references.pmid: 24401647
references.citation: AIDS. 2009 Jan 2;23(1):41-50
references.pmid: 19050385
references.citation: AIDS Patient Care STDS. 1999 Jul;13(7):415-26
references.pmid: 10870595
references.citation: J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61
references.pmid: 18156992
references.citation: Int J Cancer. 2008 Jul 1;123(1):187-94
references.pmid: 18435450
references.citation: JAMA. 1999 May 19;281(19):1822-9
references.pmid: 10340370
references.citation: ScientificWorldJournal. 2009 Feb 15;9:102-8
references.pmid: 19219374
references.citation: Prev Med. 2002 Mar;34(3):386-92
references.pmid: 11902857